MoonLake Immunotherapeutics
MLTX
23 hedge funds and large institutions have $190M invested in MoonLake Immunotherapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 19 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more capital invested
Capital invested by funds: $123M → $190M (+$66.7M)
1.8% more ownership
Funds ownership: 96.95% → 98.75% (+1.8%)
15% less funds holding
Funds holding: 27 → 23 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$137M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.6M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$6.29M |
| 5 |
RI
RTW Investments
New York
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$7.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$7.26M |
| 3 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
-$6.35M |
| 4 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$5.1M |
| 5 |
AWG
Alpha Wave Global
New York
|
-$4.49M |
MLTX Hedge Fund Activity: Q2 2022 in Review
23 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2022, worth a combined $190M — up 54% from $123M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MLTX and 15 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $137M. The largest seller was 683 Capital Management, exiting entirely with an estimated $7.9M sold.
- 23 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2022, down from 27 in Q1 2022.
- Funds reported $190M of MoonLake Immunotherapeutics stock for Q2 2022, up 54% quarter-over-quarter.
- 15 funds opened new MoonLake Immunotherapeutics positions in Q2 2022 and 19 closed out, a net change of -4 holders.
- The largest MoonLake Immunotherapeutics buyer in Q2 2022 was BVF Inc, an estimated $137M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2022 was 683 Capital Management, an estimated $7.9M sold.
Based on aggregated 13F filings for Q2 2022.